Terence Flynn
Stock Analyst at Morgan Stanley
(3.87)
# 631
Out of 4,944 analysts
199
Total ratings
59%
Success rate
6.39%
Average return
Main Sectors:
Stocks Rated by Terence Flynn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BHVN Biohaven | Maintains: Overweight | $63 → $54 | $13.47 | +300.89% | 3 | Aug 12, 2025 | |
| PFE Pfizer | Maintains: Equal-Weight | $32 → $33 | $24.65 | +33.87% | 18 | Aug 6, 2025 | |
| AMGN Amgen | Maintains: Equal-Weight | $330 → $333 | $284.98 | +16.85% | 9 | Aug 6, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $250 → $255 | $198.64 | +28.37% | 17 | Aug 1, 2025 | |
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $171 → $176 | $172.78 | +1.86% | 23 | Jul 17, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Equal-Weight | $17 → $16 | $10.02 | +59.68% | 5 | Jul 15, 2025 | |
| RPRX Royalty Pharma | Maintains: Overweight | $51 → $54 | $35.86 | +50.59% | 12 | Jul 10, 2025 | |
| MRK Merck & Co. | Maintains: Equal-Weight | $99 → $98 | $80.30 | +22.04% | 17 | Jul 10, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Underweight | $36 → $34 | $46.55 | -26.96% | 11 | Jul 10, 2025 | |
| BNTX BioNTech SE | Maintains: Overweight | $132 → $133 | $111.00 | +19.82% | 4 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $1,133 → $1,135 | $639.43 | +77.50% | 20 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $348 → $328 | $301.39 | +8.83% | 10 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $11 | $6.80 | +61.88% | 9 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $22 | $9.67 | +127.51% | 6 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $10 | $9.05 | +10.50% | 10 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $30 → $32 | $56.60 | -43.46% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $56 → $11 | $10.86 | +1.29% | 5 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $118 | $18.74 | +529.67% | 1 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $36 | $4.46 | +707.17% | 1 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1 → $8 | $2.24 | +257.14% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $246 → $436 | $128.93 | +238.17% | 3 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $429.93 | - | 2 | Oct 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $9.25 | - | 1 | Jul 21, 2017 |
Biohaven
Aug 12, 2025
Maintains: Overweight
Price Target: $63 → $54
Current: $13.47
Upside: +300.89%
Pfizer
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $32 → $33
Current: $24.65
Upside: +33.87%
Amgen
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $330 → $333
Current: $284.98
Upside: +16.85%
AbbVie
Aug 1, 2025
Maintains: Overweight
Price Target: $250 → $255
Current: $198.64
Upside: +28.37%
Johnson & Johnson
Jul 17, 2025
Maintains: Equal-Weight
Price Target: $171 → $176
Current: $172.78
Upside: +1.86%
Nurix Therapeutics
Jul 15, 2025
Maintains: Equal-Weight
Price Target: $17 → $16
Current: $10.02
Upside: +59.68%
Royalty Pharma
Jul 10, 2025
Maintains: Overweight
Price Target: $51 → $54
Current: $35.86
Upside: +50.59%
Merck & Co.
Jul 10, 2025
Maintains: Equal-Weight
Price Target: $99 → $98
Current: $80.30
Upside: +22.04%
Bristol-Myers Squibb Company
Jul 10, 2025
Maintains: Underweight
Price Target: $36 → $34
Current: $46.55
Upside: -26.96%
BioNTech SE
Jul 10, 2025
Maintains: Overweight
Price Target: $132 → $133
Current: $111.00
Upside: +19.82%
Jul 10, 2025
Maintains: Overweight
Price Target: $1,133 → $1,135
Current: $639.43
Upside: +77.50%
Jul 10, 2025
Maintains: Equal-Weight
Price Target: $348 → $328
Current: $301.39
Upside: +8.83%
May 9, 2025
Maintains: Equal-Weight
Price Target: $12 → $11
Current: $6.80
Upside: +61.88%
May 9, 2025
Maintains: Overweight
Price Target: $24 → $22
Current: $9.67
Upside: +127.51%
May 5, 2025
Maintains: Equal-Weight
Price Target: $15 → $10
Current: $9.05
Upside: +10.50%
Feb 14, 2025
Maintains: Underweight
Price Target: $30 → $32
Current: $56.60
Upside: -43.46%
Jan 27, 2025
Downgrades: Equal-Weight
Price Target: $56 → $11
Current: $10.86
Upside: +1.29%
Sep 23, 2024
Initiates: Overweight
Price Target: $118
Current: $18.74
Upside: +529.67%
Jul 23, 2024
Initiates: Overweight
Price Target: $36
Current: $4.46
Upside: +707.17%
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $1 → $8
Current: $2.24
Upside: +257.14%
Jun 14, 2021
Maintains: Neutral
Price Target: $246 → $436
Current: $128.93
Upside: +238.17%
Oct 2, 2017
Upgrades: Buy
Price Target: n/a
Current: $429.93
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $9.25
Upside: -